OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
P/E ratio for OKYO Pharma Limited (OKYO)
P/E ratio as of 2024: -2563.69
According to OKYO Pharma Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2563.69. At the end of 2023 the company had a P/E ratio of -2.82.
P/E ratio history for OKYO Pharma Limited from 2008 to 2024
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2024 | -2563.69 |
| 2023 | -2.82 |
| 2022 | -652.68 |
| 2021 | -526.95 |
| 2020 | -1124.11 |
| 2019 | -290.71 |
| 2018 | -49.03 |
| 2017 | -5703.33 |
| 2016 | -1171.11 |
| 2015 | -111.50 |
| 2014 | -46.92 |
| 2013 | -144.89 |
| 2012 | -121.79 |
| 2011 | -495.53 |
| 2010 | 62.20 |
| 2009 | 57.59 |
| 2008 | -34.16 |